Stock Quote
Myriad Genetics Inc (MYGN.O) (Nasdaq)
sector: Healthcare .
industry: Pharmaceuticals - Generic & Specialty ยท
View MYGN on other exchanges
$23.81
23 Nov 2009
+0.89%
$23.81
--
1,625,580
$24.27
$23.62
$44.90
$22.38
0.25
2,316,195
MYGN.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Henderson, John | Chairman of the Board | -- |
| Meldrum, Peter | President, Chief Executive Officer, Director | 4,061,076 |
| Gilbert, Walter | Vice Chairman of the Board | -- |
Profile
Myriad Genetics, Inc. is a healthcare company focused on the development and marketing of molecular diagnostic products. The Company is focused on providing physicians with information that guide the healthcare management of their patients to prevent disease, delay the onset of disease, or catch the... Full Description
Company Address
Myriad Genetics Inc
320 Wakara Way
Salt Lake City UT 84108
P: +1801.5843600
F: +1801.5843640
320 Wakara Way
Salt Lake City UT 84108
P: +1801.5843600
F: +1801.5843640
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Response Genetics, Inc. | $1.35 | -0.14 |
| Nanosphere, Inc. | $6.39 | +0.13 |
| Genomic Health, Inc. | $19.38 | +0.09 |
| MYGN.O | Industry | |
|---|---|---|
| P/E(TTM) | 16.62 | 3.57 |
| P/S(TTM) | 6.70 | 0.57 |
| ROI(TTM) | 29.92 | 1.86 |
| ROE(TTM) | 29.92 | 2.51 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 0.39 |
| EPS Est. (Current Year) | 0.85 |
| Total Revenue | $85.12M |
| Net Income | $30.44M |
| EPS | $0.31 |
